Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6043 With or Without Bevacizumab and/or Chemotherapy in Advanced Solid Tumors
NCT07833735Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
A Phase 2 trial of SYS6043 in solid tumor, ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SYS6043
03
Conditions
solid tumorovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07833735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07833735.